myalgic encephalomyelitis

TWiV Special: David Tuller is PACEman

David Tuller returns to provide an update of his investigative work to expose the methodological and ethical problems with the PACE trial for ME/CFS. <span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span>&lt;span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”&gt;&lt;/span&gt;&amp;lt;span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”&amp;gt;&amp;lt;/span&amp;gt;&amp;amp;lt;span data-mce-type=”bookmark” …

TWiV Special: David Tuller is PACEman Read More »

TWiV Special: Trial by Error, Continued

David Tuller returns to discuss the continuing saga of the UK’s PACE trial for chronic fatigue syndrome, including the accusation that he is engaging in libelous blogging. You can find this TWiV Special at microbe.tv/twiv, or listen below. Click arrow to play Download TWiV Special (31 MB .mp3, 50 min) Subscribe (free): iTunes, RSS, email Become a patron of TWiV!

Intestinal dysbiosis in ME/CFS patients

The microbes that live on and in us provide a host of functions that are essential for our health. Changes in the composition of these microbial communities correlate with a variety of disease states. Results of a new study (link) reveal altered populations of intestinal bacteria and metabolic disturbances in ME/CFS patients. The study subjects were …

Intestinal dysbiosis in ME/CFS patients Read More »

Trial By Error, Continued: Why has the PACE Study’s “Sister Trial” Been “Disappeared” and Forgotten?

By David Tuller, DrPH David Tuller is academic coordinator of the concurrent masters degree program in public health and journalism at the University of California, Berkeley. In 2010, the BMJ published the results of the Fatigue Intervention by Nurses Evaluation, or FINE. The investigators for this companion trial to PACE, also funded by the Medical …

Trial By Error, Continued: Why has the PACE Study’s “Sister Trial” Been “Disappeared” and Forgotten? Read More »

B cell depletion benefits ME/CFS patients

Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) showed clinical improvement after extended treatment with the anti-B-cell monoclonal antibody rituximab. This result suggests that in a subset of patients, ME/CFS might be an autoimmune disease. Rituximab is a monoclonal antibody against a protein on the surface of B cells known as CD20. When the antibody is given to …

B cell depletion benefits ME/CFS patients Read More »

Scroll to Top